CRP and cardiomyopathy: In STEP-HFpEF, semaglutide 2.4 OW improved Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) (+ 7.8 points), 6-minute walk distance (6MWD) (+ 20.3 m), reduced C Reactive Protein (CRP) (−43.5% vs. −7.3%) and body weight (− 13.3% vs. − 2.6%), and showed a lower, though exploratory, HF event rate (HR 0.08; 95% CI 0.00–0.42) [5].